NCT00794274已完成2 期
The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- Improvement in skin lesions as assessed by a Sarcoidosis Skin Activity and Severity Index (SASI) .
研究概览
简要总结
To determine whether CC-10004, a phosphodiesterase inhibitor, is useful in treating chronic cutaneous sarcoidosis.
详细描述
This will be an open label, phase II trial of CC-10004 for chronic cutaneous sarcoidosis. It will include two centers (University of Cincinnati and Medical University of South Carolina). The study will evaluate patients with chronic disease who are on a stable treatment regimen and have no significant change in their Sarcoidosis Skin Activity and Severity Index score (SASI) at two visits at least one month apart.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must understand and voluntarily sign an informed consent form
- •Must be male or female and aged ≥ 18 years at time of consent
- •Must be able to adhere to the study visit schedule and other protocol requirements
- •Patients with sarcoidosis as defined by the ATS/ERS/WASOG statement on sarcoidosis as defined by the clinical presentation consistent with sarcoidosis, biopsy finding granulomas, and no alternative for the cause of the granulomas, such as tuberculosis
- •Patients must have chronic cutaneous skin lesions while taking chronic therapy (corticosteroids, methotrexate (max 10mg/week), azathioprine, hydroxychloroquine, cyclophosphamide, minocycline, doxycycline and chloroquine), in which the dose has not been altered in the three months prior to starting the study.
- •Must have two visits within the previous 1-6 months (at least one month apart) with stable skin lesions, such as a SASI score was within one point for each of the features of the lesion.
- •Must meet the following laboratory criteria:
- •Hemoglobin > 9 g/dL
- •Hematocrit ≥ 27%
- •White blood cell (WBC) count ≥ 3000 (≥ 3.0 X 109/L) and < 20,000 (< 20 X 109/L)
- •Neutrophils ≥ 1500 (≥ 1.5 X 109/L)
- •Platelets ≥ 100,000 (≥ 100 X 109/L)
- •Serum creatinine ≤ 1.5 mg/dL (≤ 132.6 μmol/L)
- •Total bilirubin < 2.0 mg/dL
- •Aspartate transaminase (AST [serum glutamic oxaloacetic transaminase, SGOT]) and alanine transaminase (ALT [serum glutamate pyruvic transaminase, SGPT]) < 1.5x upper limit of normal (ULN)
- •Females of childbearing potential (FCBP)‡ must have a negative urine pregnancy test at screening (Visit 1). In addition, sexually active FCBP must agree to use TWO of the following adequate forms of contraception while on study medication: oral, injectable, or implantable hormonal contraceptives; tubal ligation; intrauterine device; barrier contraceptive or vasectomized partner. A FCBP must agree to have pregnancy tests every 28 days while on study medication.
- •Males (including those who have had a vasectomy) must agree to use barrier contraception (latex condoms) when engaging in sexual activity with FCBP while on study medication and for 84 days after taking the last dose of study medication.
排除标准
- •History of any clinically significant cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic, or other major diseases (not including pulmonary sarcoidosis)
- •Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
- •Pregnant or lactating female
- •History of active Mycobacterium tuberculosis infection (any subspecies) within 3 years prior to the screening visit. Infections that occurred > 3 years prior to entry must have been effectively treated.
- •History of incompletely treated latent Mycobacterium tuberculosis infection (as indicated by a positive Purified Protein Derivative [PPD] skin test or in vitro test [T-SPOT®.TB, QuantiFERON Gold®].
- •Clinically significant abnormality on the chest x-ray (CXR) at screening not due to sarcoidosis
- •Use of any investigational medication within 28 days.
- •Any clinically significant abnormality on 12-lead ECG at screening
- •Positive human immunodeficiency virus (HIV), hepatitis B, or hepatitis C laboratory test result indicating active infection at screening
- •History of malignancy within previous 5 years (except for treated basal-cell skin carcinoma(s) and/or fewer than 3 treated squamous-cell skin carcinomas)
- •Use of infliximab, etanercept, adalimumab, pentoxifylline, or thalidomide in the prior three months.
研究组 & 干预措施
Open label drug
Experimental
Drug: CC-100004
After the screening period, subjects will receive CC-10004 20mg by mouth BID for 84 days. The 84-day duration of treatment is expected to provide adequate time to assess the short-term efficacy and safety of CC-10004 in a population of subjects with chronic cutaneous sarcoidosis
干预措施: CC-100004 (Drug)
结局指标
主要结局
Improvement in skin lesions as assessed by a Sarcoidosis Skin Activity and Severity Index (SASI) .
时间窗: 6 months
次要结局
- To determine the safety (type, frequency, severity, and relationship of adverse events to study treatment) of CC-10004 in patients with chronic cutaneous sarcoidosis.(6 months)
- Improvement of global score of sarcoidosis using a visual analogue scale (VAS) by both the patient and a separate VAS by the physician.(6 months)
- Change in the quality of life using the Sarcoidosis Health Questionnaire and Short Form-36 (SF-36).(6 months)
- Change in genomic and proteomic expression of cytokines in paired skin biopsies (non-facial lesions).(6 months)
- Improvement in pulmonary status, specifically the six-minute walk test, dyspnea score, and forced vital capacity (FVC).(6 months)
研究者
Robert P Baughman
Professor of Medicine
University of Cincinnati
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus PatientsDiscoid Lupus ErythematosusNCT00708916NYU Langone Health8
已完成
2 期
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of KRP-104 in Patients With Type 2 Diabetes Inadequately Controlled on Metformin AloneType 2 DiabetesNCT00525330ActivX Biosciences, Inc.213
已完成
2 期
Safety and Efficacy Study of MRE0094 to Treat Chronic, Neuropathic, Diabetic Foot UlcersFoot Ulcer, DiabeticDiabetes ComplicationsNCT00312364Pfizer322
已完成
1 期
Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy SubjectsPsoriasisNCT04837235Tianjin Hemay Pharmaceutical Co., Ltd12
已完成
3 期
The Effectiveness of Coconut Oil Cream as a Prevention Treatment for Occupational Hand Dermatitis Among Batik WorkersHand DermatosesNCT03617068Fakultas Kedokteran Universitas Indonesia32